CLRB Cellectar Biosciences, Inc.
Financings ·
Holders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026.
Holders exercised warrants for 1,048,094 shares at $5.25 and received new warrants at $6.00. Cellectar says cash should last into the third quarter of 2026.
Holders of warrants for 8,301,322 shares agreed to exercise at a reduced price of $0.3041 per share. Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025.
The company found that certain warrants and preferred stock issued before 2023 had not been accounted for properly. It estimated cash of $34.3 million at September 30, 2024.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $11.5 million | $26.1 million |
| Net income (loss) | -$21.8 million | -$44.6 million |
| Cash from operations | -$23.1 million | -$47.6 million |
| Cash and equivalents | $13.2 million | $23.3 million |
Cellectar Biosciences, Inc. trades under the ticker CLRB on NASDAQ.
Cellectar Biosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Cellectar Biosciences, Inc. is 1279704. Its filings are on SEC EDGAR.
9,452,108 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Cellectar Biosciences, Inc. under United States.
Our directory classifies Cellectar Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cellectar Biosciences, Inc. is US15117F8804.
aibio.space lists Cellectar Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Cellectar Biosciences, Inc. reported a net loss of $21.8 million for the fiscal year ended Dec 31, 2025, and used $23.1 million of cash in operations, per its annual report to the SEC.
$11.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$34.0 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Cellectar Biosciences, dated Oct 10, 2025: "Cellectar Biosciences gets about $5.8 million gross from warrant inducement, issues new warrants". Holders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026. Source.
Our latest financing story, dated Oct 10, 2025: "Cellectar Biosciences gets about $5.8 million gross from warrant inducement, issues new warrants". Holders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026. Source.
From our story: Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025. Source.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,3.03,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio